

Appl. No. 09/692,504
Amdt. dated June 5, 2003
Reply to Final Office Action of March 17, 2003

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 (Currently Amended) A method of enhancing, stimulating or potentiating the differentiation of T-cells into the Th2 subtype instead of the Th1 subtype, comprising contacting said T-cells with an effective amount of a TCCR antagonist, wherein the TCCR comprises SEQ ID NO: 1 or 2 and the antagonist comprises an antibody or antibody fragment.

Claim 2 (Original) The method of claim 1, wherein the enhancing, stimulating or potentiating occurs in a mammal and the effective amount is a therapeutically effective amount.

Claim 3 (Currently Amended) A method of treating a Th1-mediated disease in a mammal comprising ~~administering~~ administering to said mammal ~~an therapeutically effective amount of an anti-TCCR antibody or antibody fragment effective to reduce a Th1 response as compared with a non-treated control, where the TCCR comprises the amino acid sequence of SEQ ID NO: 1 or 2 a therapeutically effective amount of a TCCR polypeptide antagonist.~~

Claim 4 (Original) The method of claim 3, wherein the Th1-mediated disease is selected from the group consisting of autoimmune inflammatory disease and allograft rejection.

Claim 5 (Original) The method of claim 4, wherein the autoimmune inflammatory disease is selected from the group consisting of allergic encephalomyelitis, multiple sclerosis, insulin-dependent diabetes mellitus, autoimmune uveoretinitis, inflammatory bowel disease and autoimmune thyroid disease.

Claims 6 – 10 (Canceled)

Claim 11 (Currently Amended) The method of claim 3, wherein the antibody ~~antagonist~~ is a monoclonal antibody.

Claim 12 (Currently Amended) The method of claim ~~3~~ 11 wherein the antibody has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.

Claim 13 (Original) The method of claim 3 wherein the antagonist is an antibody fragment or a single-chain antibody.

Claims 14 – 34 (Canceled)